Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
727 hari yang lalu
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
982 hari yang lalu
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
1009 hari yang lalu
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
1081 hari yang lalu
Thai Stock Market Tipped To Open In The Green
The Thai stock market on Thursday ended the two-day slide in which it had slipped almost 15 points or 1.2 percent. The Stock Exchange of Thailand now sits just above the 1,250-point plateau and it may open to the upside again on Friday.
RTTNews
|
15 minit yang lalu
Japanese Market Notably Lower
Giving up some of the gains in the previous two sessions, the Japanese market is notably lower on Friday, despite the broadly positive cues from Wall Street overnight. The Nikkei 225 is falling well below the 42,700 level, with weakness across most sectors led by exporters and technology stocks.
RTTNews
|
33 minit yang lalu
Additional Support Predicted For Indonesia Shares
The Indonesia stock market has moved higher in two consecutive trading days, gathering almost 50 points or 0.6 percent in that span. The Jakarta Composite Index now sits just above the 7,950-point plateau and it may add to its winnings on Friday.
RTTNews
|
45 minit yang lalu
Australian Market Slightly Lower
The Australian stock market is trading slightly lower on Friday, giving up some of the gains in the previous two sessions, despite the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is staying below the 9,000 mark, with weakness in mining and financial stocks partially offset by gains in energy and technology stocks.
RTTNews
|
54 minit yang lalu
